Migraine Ergot Alkaloids

Ergotamine and dihydroergotamine — mechanisms, pharmacokinetics, and clinical positioning

Migraine termination by ergot alkaloids and by triptans works through the same receptor — serotonin 5-HT1B/1D — but the drugs arrived at it by different paths and carry different pharmacological baggage. The mechanism card explains the shared endpoint; the comparison card explains why triptans largely replaced ergots despite the shared target.

The trigeminovascular mechanism is what connects the receptor to the headache. Serotonin 5-HT1B agonism constricts cranial vessels; 5-HT1D agonism inhibits trigeminal nerve terminals and blocks release of calcitonin gene-related peptide and substance P. Ergotamine hits both targets, but so does sumatriptan — the difference is that ergotamine also hits alpha-adrenergic receptors and serotonin 2A receptors, which is the source of its peripheral vasoconstriction liability.

Ergotamine's pharmacokinetics are the other major clinical limitation. Oral bioavailability is 1–3% under fasting conditions and still only moderate even with the caffeine that is commonly co-formulated to enhance absorption. Dihydroergotamine is preferred intravenously for this reason: the intravenous route bypasses the absorption barrier and produces rapid, predictable plasma levels.

Medication overuse headache is a class effect and a clinical trap. Using ergotamine or triptans more than 10 days per month transforms episodic migraine into a daily headache syndrome that is driven by the medication rather than by the underlying disease. The treatment is withdrawal, which initially worsens headache before improving it.

The interaction and contraindication rule box carries the identical cytochrome P450 3A4 warning from Module 1 plus the ergotamine-specific addition: concurrent use with triptans risks serotonin syndrome, and the combination should be separated by at least 24 hours. Cardiovascular disease is an absolute contraindication for the same reason it was in Module 2 — coronary vasospasm at therapeutic doses.

Mechanism of Migraine Termination

Ergotamine / Dihydroergotamine Trigeminovascular Mechanism

5-HT1B agonism: Cranial vasoconstriction → reduces pulsation driving headache
5-HT1D agonism: Inhibits trigeminal nerve terminals → blocks calcitonin gene-related peptide and substance P release → reduces neurogenic inflammation
Alpha-adrenergic agonism: Additional vasoconstriction (peripheral and cranial) — source of cardiovascular liability
Ergotamine also has 5-HT2A partial agonism — adds uterine and vascular smooth muscle effects not seen with triptans

Ergots vs. Triptans

Triptans (e.g., Sumatriptan) Selective, Better Tolerated

Selective 5-HT1B/1D agonists only — no alpha-adrenergic activity
Predictable oral bioavailability
Lower peripheral vasoconstriction risk
Now first-line for acute migraine
Multiple routes: oral, subcutaneous, intranasal, transdermal

Ergots Broader Receptor Activity, Niche Use

Non-selective: 5-HT1B/1D + alpha-adrenergic + 5-HT2A
Ergotamine oral bioavailability 1–3% (poor, erratic)
Dihydroergotamine IV/IM: superior bioavailability and faster onset
Niche use: status migrainosus, triptan-refractory migraine
Caffeine co-formulation improves ergotamine absorption

Key Adverse Effects and Pharmacokinetics

Medication Overuse Headache

Limit use to ≤10 days/month
Daily use transforms episodic → chronic daily headache
Treatment: withdrawal (worsens before improving)

Vasoconstriction

Peripheral vasoconstriction → cold extremities, tingling
Coronary vasospasm at therapeutic doses
Absolute contraindication in cardiovascular disease

Retroperitoneal Fibrosis

Rare but serious with prolonged use
Also pulmonary and cardiac fibrosis
5-HT2B agonism implicated (same mechanism as methysergide)

Drug Interactions and Contraindications

Cytochrome P450 3A4 inhibitors (azole antifungals, macrolides, ritonavir): markedly increase ergot levels → severe vasospasm. Combination is contraindicated.

Triptans + ergots: Do not combine within 24 hours — additive vasoconstriction and serotonin syndrome risk.

Absolute contraindications: Coronary artery disease, peripheral vascular disease, hypertension, pregnancy, hepatic or renal impairment.

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S	Pathophysiology of migraine: a disorder of sensory processing	Physiol Rev. 2017;97(2):553–622
Silberstein SD, McCrory DC	Ergotamine and dihydroergotamine: history, pharmacology, and efficacy	Headache. 2003;43(2):144–166
Tfelt-Hansen P, Saxena PR, Dahlof C, et al.	Ergotamine in the acute treatment of migraine: a review and European consensus	Brain. 2000;123(1):9–18
Raskin NH	Repetitive intravenous dihydroergotamine as therapy for intractable migraine	Neurology. 1986;36(7):995–997
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ	Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials	Lancet. 2001;358(9294):1668–1675
Diener HC, Limmroth V	Medication-overuse headache: a worldwide problem	Lancet Neurol. 2004;3(8):475–483
Dresser GK, Spence JD, Bailey DG	Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition	Clin Pharmacokinet. 2000;38(1):41–57
Westphal JF	Macrolide-induced clinically relevant drug interactions with cytochrome P450 3A4: an update focused on clarithromycin, azithromycin and dirithromycin	Br J Clin Pharmacol. 2000;50(4):285–295
Moskowitz MA	Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine	Trends Pharmacol Sci. 1992;13(8):307–311
Ibraheem JJ, Paalzow L, Tfelt-Hansen P	Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers	Br J Clin Pharmacol. 1983;16(6):695–699
Schiff PL	Ergot and its alkaloids	Am J Pharm Educ. 2006;70(5):98
Matossian MK	Poisons of the Past: Molds, Epidemics, and History	Yale University Press; 1989
Vaglio A, Salvarani C, Buzio C	Retroperitoneal fibrosis	Lancet. 2006;367(9506):241–251

Author / Organization

Title

Source

Katzung BG, ed.

Basic and Clinical Pharmacology. 15th ed.

McGraw-Hill; 2021

Brunton LL, Knollmann BC, eds.

Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.

McGraw-Hill; 2023

Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S

Pathophysiology of migraine: a disorder of sensory processing

Physiol Rev. 2017;97(2):553–622

Silberstein SD, McCrory DC

Ergotamine and dihydroergotamine: history, pharmacology, and efficacy

Headache. 2003;43(2):144–166

Tfelt-Hansen P, Saxena PR, Dahlof C, et al.

Ergotamine in the acute treatment of migraine: a review and European consensus

Brain. 2000;123(1):9–18

Raskin NH

Repetitive intravenous dihydroergotamine as therapy for intractable migraine

Neurology. 1986;36(7):995–997

Ferrari MD, Roon KI, Lipton RB, Goadsby PJ

Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials

Lancet. 2001;358(9294):1668–1675

Diener HC, Limmroth V

Medication-overuse headache: a worldwide problem

Lancet Neurol. 2004;3(8):475–483

Dresser GK, Spence JD, Bailey DG

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

Clin Pharmacokinet. 2000;38(1):41–57

Westphal JF

Macrolide-induced clinically relevant drug interactions with cytochrome P450 3A4: an update focused on clarithromycin, azithromycin and dirithromycin

Br J Clin Pharmacol. 2000;50(4):285–295

Moskowitz MA

Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine

Trends Pharmacol Sci. 1992;13(8):307–311

Ibraheem JJ, Paalzow L, Tfelt-Hansen P

Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers

Br J Clin Pharmacol. 1983;16(6):695–699

Schiff PL

Ergot and its alkaloids

Am J Pharm Educ. 2006;70(5):98

Matossian MK

Poisons of the Past: Molds, Epidemics, and History

Yale University Press; 1989

Vaglio A, Salvarani C, Buzio C

Retroperitoneal fibrosis

Lancet. 2006;367(9506):241–251